Wells Fargo emphasized that Metsera’s long half-life drugs may provide improved tolerability by enabling gradual buildup of drug exposure and avoiding fluctuations that increase adverse events. The ...

Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera” or the "Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.

Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...

Metsera has also applied HALO to the GLP-1 drug candidate in its pipeline, MET-097i, which is currently in Phase 2b testing as a monotherapy.

Metsera Inc.’s shares jumped after the obesity startup shared better-than-expected data on a weight-loss shot that would allow patients to go from weekly to monthly dosing.

Investing.com -- Shares of Metsera, Inc. (Nasdaq:MTSR) surged 18% following the announcement of positive Phase 1 trial results for its once-monthly amylin analog candidate, MET-233i. The New York ...

NEW YORK - Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company valued at $2.89 billion, today revealed positive topline results from its Phase 1 clinical trial for MET-233i ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial and the potential to have longer-lasting effects than current weight loss treatments on the ...